

# Alzheimer's Disease Drug Market 2018 Global Industry – Key Players, Size, Trends, Opportunities, Growth and Forecast 2025

PUNE, INDIA, June 29, 2018

/EINPresswire.com/ --

WiseGuyReports.com Presents “Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Alzheimer's Disease Drug Market 2018, Forecast to 2023” New Document to its Studies Database

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

## Scope of the Report:

This report focuses on the Alzheimer's Disease Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

In the last several years, global market of alzheimer's disease drug change huge.

The classification of alzheimer's disease drug includes Memantine, Donepezil, Rivastigmine and Others, and the proportion of Memantine in 2016 is about 49.28%. The market for Donepezil, is decrease quickly in past five years.

Alzheimer's disease drug are widely used for Early to Moderate, Moderate to Severe stage treatment. The most proportion of alzheimer's disease drug used to Moderate to Severe, and the market share in 2016 is 55.82%.

The worldwide market for Alzheimer's Disease Drug is expected to grow at a CAGR of roughly -11.3% over the next five years, will reach 1580 million US\$ in 2023, from 2870 million US\$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Allergan

Eisai

Novartis

Daiichi Sankyo

Merz Pharma

Pfizer

Johnson & Johnson

Lundbeck

Request For Sample Report @ <https://www.wiseguyreports.com/sample-request/3245665-global-north-america-europe-asia-pacific-south-america>

Market Segment by Regions, regional analysis covers  
North America (United States, Canada and Mexico)  
Europe (Germany, France, UK, Russia and Italy)  
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)  
South America (Brazil, Argentina, Colombia etc.)  
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers  
Donepezil  
Memantine  
Rivastigmine

Market Segment by Applications, can be divided into  
Early to Moderate Stages  
Moderate to Severe Stages

Complete Report Details @ <https://www.wiseguyreports.com/reports/3245665-global-north-america-europe-asia-pacific-south-america>

## Table Of Contents:

- 1 Market Overview
  - 1.1 Alzheimer's Disease Drug Introduction
  - 1.2 Market Analysis by Type
    - 1.2.1 Donepezil
    - 1.2.2 Memantine
    - 1.2.3 Rivastigmine
  - 1.3 Market Analysis by Applications
    - 1.3.1 Early to Moderate Stages
    - 1.3.2 Moderate to Severe Stages
  - 1.4 Market Analysis by Regions
  - 1.5 Market Dynamics
    - 1.5.1 Market Opportunities
    - 1.5.2 Market Risk
    - 1.5.3 Market Driving Force
- 2 Manufacturers Profiles
  - 2.1 Allergan
    - 2.1.1 Business Overview
      - 2.1.1.1 Allergan Description
      - 2.1.1.2 Allergan Headquarter, Main Business and Finance Overview
    - 2.1.2 Allergan Alzheimer's Disease Drug Product Introduction

- 2.1.2.1 Alzheimer's Disease Drug Production Bases, Sales Regions and Major Competitors
- 2.1.2.2 Alzheimer's Disease Drug Product Information
- 2.1.3 Allergan Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  - 2.1.3.1 Allergan Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  - 2.1.3.2 Global Allergan Alzheimer's Disease Drug Market Share in 2017
- 2.2 Eisai
  - 2.2.1 Business Overview
    - 2.2.1.1 Eisai Description
    - 2.2.1.2 Eisai Headquarter, Main Business and Finance Overview
  - 2.2.2 Eisai Alzheimer's Disease Drug Product Introduction
    - 2.2.2.1 Alzheimer's Disease Drug Production Bases, Sales Regions and Major Competitors
    - 2.2.2.2 Alzheimer's Disease Drug Product Information
  - 2.2.3 Eisai Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    - 2.2.3.1 Eisai Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    - 2.2.3.2 Global Eisai Alzheimer's Disease Drug Market Share in 2017
- 2.3 Novartis
  - 2.3.1 Business Overview
    - 2.3.1.1 Novartis Description
    - 2.3.1.2 Novartis Headquarter, Main Business and Finance Overview
  - 2.3.2 Novartis Alzheimer's Disease Drug Product Introduction
    - 2.3.2.1 Alzheimer's Disease Drug Production Bases, Sales Regions and Major Competitors
    - 2.3.2.2 Alzheimer's Disease Drug Product Information
  - 2.3.3 Novartis Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    - 2.3.3.1 Novartis Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    - 2.3.3.2 Global Novartis Alzheimer's Disease Drug Market Share in 2017
- 2.4 Daiichi Sankyo
  - 2.4.1 Business Overview
    - 2.4.1.1 Daiichi Sankyo Description
    - 2.4.1.2 Daiichi Sankyo Headquarter, Main Business and Finance Overview
  - 2.4.2 Daiichi Sankyo Alzheimer's Disease Drug Product Introduction
    - 2.4.2.1 Alzheimer's Disease Drug Production Bases, Sales Regions and Major Competitors
    - 2.4.2.2 Alzheimer's Disease Drug Product Information
  - 2.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    - 2.4.3.1 Daiichi Sankyo Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    - 2.4.3.2 Global Daiichi Sankyo Alzheimer's Disease Drug Market Share in 2017
- 2.5 Merz Pharma
  - 2.5.1 Business Overview
    - 2.5.1.1 Merz Pharma Description
    - 2.5.1.2 Merz Pharma Headquarter, Main Business and Finance Overview
  - 2.5.2 Merz Pharma Alzheimer's Disease Drug Product Introduction
    - 2.5.2.1 Alzheimer's Disease Drug Production Bases, Sales Regions and Major Competitors
    - 2.5.2.2 Alzheimer's Disease Drug Product Information
  - 2.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5.3.1 Merz Pharma Alzheimer's Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5.3.2 Global Merz Pharma Alzheimer's Disease Drug Market Share in 2017

Continued.....

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

[www.wiseguyreports.com](http://www.wiseguyreports.com)

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.